Solid Biosciences Inc. Cash and Restricted Cash
Solid Biosciences Inc. (SLDB) had Cash and Restricted Cash of $160.74 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $160.74M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $298.44M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61.89M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $63.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $160.74M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $298.44M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $61.89M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $63.29M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $140.86M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $212.60M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $82.19M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $66.33M 10-Q · filed 2025-11-03 |
| 2024-06-30 | $97.76M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $119.41M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $75.85M 10-K · filed 2026-03-19 |
| 2023-09-30 | $50.87M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $93.40M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $166.48M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $157.22M 10-K · filed 2025-03-06 |
| 2022-09-30 | $50.86M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $56.38M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $131.78M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $121.21M 10-K · filed 2024-03-13 |
| 2021-09-30 | $111.84M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $202.77M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $268.82M 10-Q · filed 2022-04-27 |
| 2020-12-31 | $155.07M 10-K · filed 2024-03-13 |
| 2020-09-30 | $25.12M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $40.77M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $53.51M 10-Q · filed 2021-05-14 |
| 2019-12-31 | $76.37M 10-K · filed 2023-03-23 |
| 2019-09-30 | $95.05M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $52.16M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $54.32M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $86.69M 10-K · filed 2022-03-14 |
| 2018-09-30 | $129.37M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $146.06M 10-Q · filed 2019-08-14 |
| 2018-03-31 | $165.07M 10-Q · filed 2019-05-13 |
| 2017-12-31 | $52.15M 10-K · filed 2021-03-15 |
| 2017-09-30 | $15.18M 10-Q · filed 2018-11-13 |
| 2017-06-30 | $32.88M 10-Q · filed 2018-08-10 |
| 2017-03-31 | $29.43M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $7.84M 10-K · filed 2020-03-12 |
| 2015-12-31 | $28.59M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |